WHO Issues Alert Over Severe Shortage of Weight-Loss Medications

Fewer than a tenth of patients that would benefit from GLP-1 drugs including Wegovy have access to them, caution the World Health Organization as it releases its initial recommendations on the medications.

Considering more than one billion people worldwide now classified as obese, it is urging increased and just access to these injectable treatments.

Per projections, more than two billion are projected to be obese by 2030 unless action is taken.

"Our new guidelines acknowledges that obesity is a lifelong illness that can be treated with holistic and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and distribution challenges are major obstacles to broad access to the injections that can help people shift significant body mass, notes the organization.

Skinny Jab Supply Crisis

Even under the current best projected outlook, the production of these medications could only cover about 100 million people – under 10% of eligible patients, according to the health organization.

The recommendation calls on governments and firms to expand availability, through strategies like licensing agreements.

Exclusive production rights on a key compound – the main ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.

The Way Obesity Jabs Operate

These medications imitate a natural hormone to delay gastric emptying, reduce hunger and boost satiety so people consume fewer calories.

Individuals commonly start to lose weight in the initial weeks of starting on the weekly injections.

Studies indicates users may regain a significant portion after a year of discontinuing the drug, as their typical appetite resume.

To be overweight or obese raises your likelihood for contracting medical conditions, like diabetes, heart disease, brain attack, and some cancers.

Excess weight concerns individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.